BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 19, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/16 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) Leerink Joshua Schimmer Upgrade Market outperform (from market perform) 7% $37.85
Schimmer upgraded based on feedback from multiple sclerosis specialists indicating Ampyra dalfampridine is "launching quickly and penetrating deeply in a highly concentrated MS population." He increased his sales estimate for 2010 and 2011 to $83M and $442M, respectively, from $66M and $253M. Acorda has rights to the sustained-release formulation of 4-aminopyridine drug from Elan Corp. plc (NYSE:ELN).
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Jefferies Eun Yang Price target Buy 0% $54.87
Yang raised her target to $62...

Read the full 743 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >